Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.78 USD
-0.12 (-3.08%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $3.77 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABUS 3.78 -0.12(-3.08%)
Will ABUS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Other News for ABUS
Amgen, Garmin among relative market leaders poised to outperform in coming months: BTIG
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Sets Q2 2024 Financial Results Date
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
Arbutus Reports Promising Hepatitis B Trial Results